Experience with dexmetomidine in the management of alcohol withdrawal syndrome for patients with cirrhosis
Introduction and Objectives: Lorazepam is the first-line treatment in patients with alcohol withdrawal syndrome (AWS). In patients with cirrhosis and AWS, the use of dexmetomidine (DXM) has been poorly studied. The objective of this study is to report the effect of DXM in patients with cirrhosis and...
Saved in:
| Main Authors: | Liliana I. Gallardo-González, Jose L. Perez-Hernandez, Maria F. Higuera-De la, Tijera, Mary C. Alegría-Ovando |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | Annals of Hepatology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268125000195 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
P-56 EXPERIENCE WITH DEXMEDETOMIDINE IN THE MANAGEMENT OF ALCOHOL WITHDRAWAL SYNDROME FOR PATIENTS WITH CIRRHOSIS
by: Liliana Ivonne Gallardo Gonzalez, et al.
Published: (2024-12-01) -
Participation of the immune response and oxidative stress in alcoholism and liver cirrhosis due to alcohol
by: Leonardo S. Juárez-Chávez, et al.
Published: (2025-04-01) -
Characteristics of overlap syndrome in Mexican patients.
by: Claudia G. Solis-Hernandez, et al.
Published: (2025-04-01) -
Emergencies in AUD: acute alcohol intoxication and alcohol withdrawal syndrome
by: Antonio Mirijello, et al.
Published: (2024-05-01) -
Response to Porres-Aguilar et al., on “Periprocedural and perioperative anticoagulation management strategies in liver cirrhosis”
by: J.A. Velarde-Ruiz Velasco, et al.
Published: (2025-01-01)